Tech Company Financing Transactions
Pliant Therapeutics Funding Round
Pliant Therapeutics, based in San Francisco, secured $100 million from Novartis Venture Fund, Agent Capital and Cormorant Asset Management.
Transaction Overview
Company Name
Announced On
3/4/2020
Transaction Type
Venture Equity
Amount
$100,000,000
Round
Series C
Investors
Proceeds Purpose
Pliant plans to use the proceeds from the financing to support the continued clinical development of PLN-74809 in idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC), as well as its ongoing drug discovery programs targeting other fibrotic diseases.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
260 Littlefield Ave.
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Pliant Therapeutics (Nasdaq: PLRX) is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Bernard Coulie
Chief Financial Officer
Keith Cummings
Chief Medical Officer
Eric Lefebvre
Vice President
Katerina Leftheris
Vice President
Scott Turner
VP - Bus. Development
Hans Hull
VP - Bus. Development
Eve-Irene Lepist
VP - Human Resources
Barbara Howes
VP - Operations
Marzena Jurek
Browse more venture capital transactions:
Prev: 3/4/2020: unitQ venture capital transaction
Next: 3/4/2020: Sourcegraph venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to report on funding rounds that are announced publicly. VC transactions reported here are sourced from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs